CG Oncology (NASDAQ:CGON) Shares Down 6.3% – Here’s What Happened

05 Jan 2026, 20:00 by Mitch Edgeman · The Markets Daily

CG Oncology, Inc. (NASDAQ:CGON – Get Free Report) traded down 6.3% during trading on Monday . The company traded as low as $40.37 and last traded at $39.16. 124,590 shares were traded during trading, a decline of 78% from the average session volume of 562,916 shares. The stock had previously closed at $41.79.

Analysts Set New Price Targets

CGON has been the topic of a number of analyst reports. Guggenheim began coverage on CG Oncology in a research note on Tuesday, October 7th. They set a “buy” rating and a $90.00 price objective on the stock. Wall Street Zen upgraded CG Oncology from a “sell” rating to a “hold” rating in a research note on Friday, October 3rd. Jones Trading assumed coverage on shares of CG Oncology in a report on Monday, September 8th. They issued a “buy” rating and a $50.00 target price for the company. Wedbush initiated coverage on CG Oncology in a research report on Thursday, December 11th. They set an “outperform” rating and a $70.00 price objective on the stock. Finally, HC Wainwright reaffirmed a “buy” rating and set a $75.00 price objective on shares of CG Oncology in a research report on Monday, September 15th. One investment analyst has rated the stock with a Strong Buy rating, eleven have issued a Buy rating, two have given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $60.58.

Get Our Latest Stock Analysis on CGON

CG Oncology Stock Performance

The stock’s 50-day moving average is $41.35 and its 200 day moving average is $34.78. The stock has a market capitalization of $3.20 billion, a PE ratio of -19.44 and a beta of 1.35.

CG Oncology (NASDAQ:CGON – Get Free Report) last released its earnings results on Friday, November 14th. The company reported ($0.57) EPS for the quarter, hitting the consensus estimate of ($0.57). The firm had revenue of $0.16 million during the quarter, compared to analyst estimates of $0.07 million. Analysts expect that CG Oncology, Inc. will post -1.31 earnings per share for the current year.

Insider Activity

In other CG Oncology news, Director Leonard E. Post sold 1,000 shares of the business’s stock in a transaction on Monday, November 17th. The shares were sold at an average price of $41.43, for a total transaction of $41,430.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director James Mulay sold 5,903 shares of the business’s stock in a transaction on Thursday, October 9th. The shares were sold at an average price of $43.99, for a total transaction of $259,672.97. The SEC filing for this sale provides additional information.

Institutional Investors Weigh In On CG Oncology

Institutional investors have recently added to or reduced their stakes in the company. Wesbanco Bank Inc. purchased a new position in CG Oncology during the 2nd quarter worth approximately $702,000. Voya Investment Management LLC increased its stake in shares of CG Oncology by 217.6% in the third quarter. Voya Investment Management LLC now owns 47,986 shares of the company’s stock worth $1,933,000 after purchasing an additional 32,877 shares during the period. CWM LLC boosted its holdings in CG Oncology by 193.5% in the 2nd quarter. CWM LLC now owns 6,193 shares of the company’s stock valued at $161,000 after purchasing an additional 4,083 shares during the period. OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC acquired a new position in shares of CG Oncology in the second quarter valued at $676,000. Finally, Franklin Resources Inc. lifted its stake in CG Oncology by 12.7% during the second quarter. Franklin Resources Inc. now owns 1,486,839 shares of the company’s stock worth $38,658,000 after purchasing an additional 167,905 shares during the period. 26.56% of the stock is currently owned by institutional investors and hedge funds.

About CG Oncology

(Get Free Report)

CG Oncology, Inc (NASDAQ: CGON) is a clinical-stage biopharmaceutical company focused on the discovery and development of novel antibody-based immunotherapies for the treatment of solid tumor cancers. The company leverages a platform-driven approach to identify and optimize antibody candidates that engage key immune checkpoints and co-stimulatory pathways within the tumor microenvironment. Its pipeline encompasses multiple preclinical programs alongside early-phase clinical trials designed to assess safety, dosing and preliminary anti-tumor activity.